A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Symptomatic Subjects With Generalized Myasthenia Gravis
Phase of Trial: Phase II
Latest Information Update: 30 May 2018
At a glance
- Drugs Immune globulin (Primary)
- Indications Myasthenia gravis
- Focus Therapeutic Use
- Sponsors Grifols
- 21 Feb 2018 Status changed from active, no longer recruiting to completed.
- 14 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 24 Aug 2017 This trial has been completed in Czech Republic.